Skip to main content
. 2013 Oct 24;174(3):449–458. doi: 10.1111/cei.12199

Fig. 3.

Fig. 3

Mesenchymal stem cells (MSC) reduce the percentage of proliferating, alloreactive CD8+CD28− T cells. Effector peripheral blood mononuclear cells (PBMC) were labelled with the proliferation marker violet proliferation dye 450 (VPD450) and stimulated with γ-irradiated allogeneic PBMC (PKH26 label) in the presence or absence of MSC (1:10; ratio MSC/effector cells) and/or 1 μg/ml belatacept. After 7 days, flow cytometric analyses were performed. (a) The percentages of proliferating CD8+ T cells (white bar) and the percentages of CD28− cells within the proliferating CD8+ T cells (grey bar) are shown; n = 8, mean ± standard error of the mean (s.e.m.); paired t-test; *P < 0·05; **P < 0·01. (b) Representative examples of allostimulated CD8+CD28− T cells in the absence and presence of belatacept and/or MSC are shown. Percentages of proliferating CD8+CD28− T cells are stated. (c) The percentages of non-proliferating CD8+ T cells (white bar) and the percentage of CD28− cells within the non-proliferating CD8+ cells (grey bar) are shown; n = 8, mean ± s.e.m.; paired t-test; *P < 0·05; **P < 0·01.